Skip to main content

Akebia Therapeutics, Inc. (AKBA)

NASDAQ: AKBA · Delayed Price · USD
2.70
-0.01 (-0.37%)
At close: Dec 8, 2021 4:00 PM
2.69
-0.01 (-0.37%)
After-hours:Dec 8, 2021 7:53 PM EST
Market Cap472.39M
Revenue (ttm)210.67M
Net Income (ttm)-299.16M
Shares Out174.96M
EPS (ttm)-1.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,916,227
Open2.72
Previous Close2.71
Day's Range2.63 - 2.73
52-Week Range2.35 - 5.14
Beta1.57
AnalystsBuy
Price Target7.17 (+165.6%)
Earnings DateNov 4, 2021

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis;...

IndustryBiotechnology
IPO DateMar 20, 2014
CEOJohn Butler
Employees379
Stock ExchangeNASDAQ
Ticker SymbolAKBA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is 7.17, which is an increase of 165.56% from the latest price.

Price Target
$7.17
(165.56% upside)
Analyst Consensus: Buy

News

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 21...

1 week ago - PRNewsWire

Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

2 weeks ago - PRNewsWire

Akebia Therapeutics to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

3 weeks ago - PRNewsWire

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -6.25% and -2.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...

1 month ago - PRNewsWire

Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appo...

1 month ago - PRNewsWire

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency ...

CAMBRIDGE, Mass., Oct. 29, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and it...

1 month ago - PRNewsWire

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones

CAMBRIDGE, Mass., Oct. 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

1 month ago - PRNewsWire

Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021

CAMBRIDGE, Mass., Oct. 18, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia...

1 month ago - PRNewsWire

7 Small-Cap Stocks to Buy From the Beat-Up Bargain Bin

Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed.

1 month ago - InvestorPlace

Akebia Therapeutics Announces September 2021 Investor Conference Schedule

CAMBRIDGE, Mass. , Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

3 months ago - PRNewsWire

Why Akebia Therapeutics Stock Is Soaring Today

Investors liked what they heard in the company's Q2 update.

4 months ago - The Motley Fool

Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -70.00% and -11.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, toda...

4 months ago - PRNewsWire

3 Hot Biotech Penny Stocks to Watch With High Volume in 2021

Are these biotech penny stocks worth investing in or not? The post 3 Hot Biotech Penny Stocks to Watch With High Volume in 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other symbols:OPKSEEL
4 months ago - PennyStocks

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and E...

LOS ANGELES--(BUSINESS WIRE)---- $AKBA #AKBA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc.

4 months ago - Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Bio...

SAN DIEGO--(BUSINESS WIRE)---- $akba #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders...

4 months ago - Business Wire

Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

4 months ago - PRNewsWire

These Penny Stocks Are Frequently Talked About on Reddit, Here's Why

Reddit penny stocks are in focus right now; here's 3 to watch The post These Penny Stocks Are Frequently Talked About on Reddit, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:EBON
4 months ago - PennyStocks

Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Which penny stocks are the best for your watchlist in 2021? The post Best 3 Penny Stocks to Watch Right Now, Worth it or Not?

Other symbols:BRQSNMTR
4 months ago - PennyStocks

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Un...

Other symbols:CYCN
6 months ago - Benzinga

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno...

6 months ago - PRNewsWire

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia

Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat's marketing application for anemia due to chronic k...

6 months ago - Benzinga

Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anem...

CAMBRIDGE, Mass. and TOKYO, June 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney diseas...

6 months ago - PRNewsWire